In contrast, Afatinib did not re-sensitize Rego-resistant SNU449-Axl- cells (Figure 4D) confirming that elevated ErbB activation is associated with Axl expression in Rego-resistant HCC cells. The gene discussed is AXL; the disease is hepatocellular carcinoma.